Inactive Instrument

Highlights Arrowhead Research Corp Nasdaq

Equities

US0427972098

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	Apr. 24	CI
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	Apr. 07	CI
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	Mar. 25	CI
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	Mar. 08	CI
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines	Feb. 07	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 06	CI
Arrowhead Pharmaceuticals' Fiscal 2023 Net Loss Widens, Revenue Falls	Nov. 29	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 29	CI
Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy	Nov. 28	CI
Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023	Nov. 13	CI
Arrowhead Pharmaceuticals' Fiscal Q3 Loss Widens, Revenue Drops	23-08-07	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-07	CI
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1	23-06-27	CI
Arrowhead Pharmaceuticals Fiscal Q2 Earnings Rise, Revenue Declines	23-05-03	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-02	CI
Arrowhead Pharmaceuticals Inc. Announces First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead	23-04-04	CI
Arrowhead Pharmaceuticals Receives $30 Million Milestone Payment from GSK for Phase 2b Trial of GSK4532990	23-04-03	MT
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases	23-02-28	CI
Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results	23-02-15	CI
Arrowhead Pharmaceuticals Fiscal Q1 Loss Narrows, Sales Jump	23-02-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arrowhead Research Corp Nasdaq

Equities

US0427972098

Highlights

Filters